Discuss This Drug

Lorlatinib

CHEBI:CHEBI_143117

Definition

A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer.

Chemical Information

Molecular Formula
C21H19FN6O2
Molecular Mass
406.421
Charge
0
SMILES
C=1C=C(C=C2C1C(=O)N(C)CC3=NN(C(=C3C=4C=NC(=C(O[C@@H]2C)C4)N)C#N)C)F
InChI
InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
InChIKey
IIXWYSCJSQVBQM-LLVKDONJSA-N

Alternative Names

  • (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile
  • loratinib
  • Lorbrena
  • lorlatinib
  • lorlatinibum
  • PF-06463922
  • PF06463922
  • PFE-PKIS 10

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

DRON_00010000
2103164
oboInOwl#hasDbXref
Wikipedia:Lorlatinib
core#notation
CHEBI:143117

Additional References

Wikipedia:Lorlatinib

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

oboInOwl#hasOBONamespace
chebi_ontology
DRON_00010000
2103164
oboInOwl#hasDbXref
Wikipedia:Lorlatinib
oboInOwl#id
CHEBI:143117
brand_name
Lorbrena
brand_name_base
Lorbrena
generic_name
lorlatinib
rxcui
2103179
product_type
DRUG FOR FURTHER PROCESSING
marketing_category
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20251231
route
ORAL
active_ingredient_strength
25 mg/1
dosage_form
TABLET, FILM COATED
marketing_start_date
20180805
package_marketing_start_date
20230103
pharm_class_moa
Organic Cation Transporter 1 Inhibitors [MoA]
nui
N0000191265
pharm_class_epc
Kinase Inhibitor [EPC]
labeler_name
U.S. Pharmaceuticals
manufacturer_name
U.S. Pharmaceuticals
product_ndc
63539-927
spl_id
5fc88709-ec95-48d9-9e9f-e6c1790f6778
active_ingredient_name
LORLATINIB
package_ndc
63539-927-01
package_description
30 TABLET, FILM COATED in 1 BOTTLE (63539-927-01)
application_number
NDA210868
unii
OSP71S83EU
spl_set_id
004f93d7-a1cd-4b67-9207-31cdcb5c5976
upc
0300690231013
RO_0000087
http://purl.obolibrary.org/obo/CHEBI_62434
oboInOwl#inSubset
http://purl.obolibrary.org/obo/chebi#3_STAR
core#notation
CHEBI:143117
pharm_class
Organic Cation Transporter 1 Inhibitors [MoA]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
has_treatment
http://purl.obolibrary.org/obo/DOID_5193
owl#annotatedSource
t112585
owl#someValuesFrom
t3350440